Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking...
Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...
pharmaphorum2d
How does global pharma company Amgen tackle safety and pharmacovigilance?
This month is our safety and pharmacovigilance focus, so pharmaphorum's Hannah Blake interviewed Amgen's Vice President of Global Regulatory Affairs and Safety, Alan Morrison, to find out Amgen's ...
Amgen Dismisses Bone Density Concerns Related to Its New Weight-Loss Drug
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
The Motley Fool28d
Is Amgen Stock a Buy?
In the second quarter, Amgen's product net sales climbed by 20% year over ... If the upcoming results confirm the favorable signs of efficacy and safety, Amgen could be on track to launch its ...
Yahoo Finance1mon
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA ...
Benzinga (Video) on MSN1d
Amgen Shares Drop 7% as Early Trial Data On Weight Loss Drug Raises Safety Concerns, Sparking Mixed Analyst Reactions
Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...